Citi Depositary Receipt Services Year-End 2017 Report

DR ACCESS PRODUCTS ABOUT CITI DEPOSITARY RECEIPT SERVICES INTERNATIONAL INVESTING TRENDS REGIONAL TRENDS GLOBAL DR TRENDS Issuer Country Industry 2 USD Value (in Millions) argenx Netherlands Pharmaceuticals, Biotechnology $115 NuCana PLC* UK Pharmaceuticals, Biotechnology $114 Secoo Holding Limited China Consumer Discretionary $111 LexinFintech China Financials $108 Four Seasons Education, Inc China Consumer Discretionary $101 Zealand Pharma Denmark Pharmaceuticals, Biotechnology $90 Verona Pharma plc* UK Pharmaceuticals, Biotechnology $88 Nightstar Therapeutics PLC* UK Pharmaceuticals, Biotechnology $86 China Rapid Finance Limited* China Financials $69 Chi Mei Materials Technology Corp Taiwan Technology Hardware & Equipment $65 Hexindai Inc.* China Diversified Financials $50 iClick Interactive Asia Group Hong Kong Media $35 Therapix Biosciences Israel Pharmaceuticals, Biotechnology $14 Immuron Limited Australia Pharmaceuticals, Biotechnology $6 Grand Total $9,355 15 Citi Depositary Receipt Services Year-End 2017 Report